Luxempart Acquires 14.9% of Medios AG

Luxempart S.A. has announced the acquisition of a 14.9% stake in Medios AG, a leader in specialty pharmaceuticals in Europe. Luxempart purchased the shares from Medios' founder Manfred Schneider, positioning itself as a new anchor shareholder.

Manfred Schneider expressed satisfaction with the deal, highlighting Luxempart's understanding of Medios' strategy and its long-term commitment. The investment resolves Schneider's shareholding succession and ensures future support for Medios.

Medios AG focuses on specialty pharmaceuticals for chronic and rare diseases, covering areas like oncology, neurology, and autoimmune diseases. The company recently diversified its operations through the acquisition of Ceban Pharmaceuticals in the Netherlands.

John Penning, Managing Director at Luxempart, praised Medios' strategic execution. Luxempart looks forward to supporting Medios in achieving its strategic and financial goals, and sees additional M&A opportunities as a key factor for growth.